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1. Introduction 
In the last two decades an enormous progress has been made in research of gene therapy, 
translating this new therapeutic approach from preclinical level to a large number of clinical 
trials, which presented encouraging results in treatment of a number of different diseases, 
from a single gene disorders to a more complex diseases, such as cancer. According to the 
Journal of Gene Medicine, at present more than 1400 human clinical trials investigating 
effects of gene therapy have been conducted, over 2/3 for therapy of cancer 
(www.wiley.com/genmed/clinical). With the advances in the field of gene therapy, this 
new therapeutic tool is steadily gaining its acceptance also in clinical veterinary medicine. In 
the last decade, a number of gene therapy clinical trials have been conducted on companion 
animals, employing both viral and nonviral vectors and evaluating its effects primarily in 
oncologic, haematologic, musculoskeletal and cardiovascular diseases (Bergmann et al., 
2003; Bodles-Brakhop et al., 2008; Dow et al., 2005; Draghia-Akli et al. 2002; Herzog et al., 
2001; Huttinger et al., 2008; Jahnke et al., 2007; Kamstock et al., 2006; Kornegay et al., 2010; 
Ohshima et al., 2009; Pavlin et al., 2011; Siddiqui et al., 2007; Sleeper et al., 2010; Z. Wang et 
al., 2007). Such clinical trials on companion animals not only play an essential role for 
progress of veterinary medicine, but also provide invaluable data for human clinical 
research, which cannot be gained from strictly preclinical research on experimental animals. 
With gene therapy having versatile applications, different approaches have been developed, 
utilizing delivery of therapeutic genes into a variety of target tissues. The first reports on 
using skeletal muscle as a target for gene delivery have been published in the 1990's and 
since then, extensive evidence has been presented that skeletal muscle is a suitable target 
tissue for gene therapy (Wolff et al., 1990). The main advantages of skeletal muscle are high 
capacity of protein synthesis and post-mitotic status of muscle fibers which enable long-
lasting transgene expression. Muscle targeted transgene delivery can lead to either local 
intramuscular secretion or systemic delivery of transgene products, thus having potential 
for treatment of both muscular and non-muscular disorders. The clinical applications of 
muscle targeted gene therapy are mainly correction of gene deficits in the muscle tissue (e.g. 
muscle dystrophies), intravascular release of therapeutic proteins resulting in expansion of 
this therapy on systemic level (e.g.immunomodulation) and DNA vaccination against tumor 
antigens or infectious agents. Intramuscular gene therapy in veterinary medicine has 
already been successfully applied for a variety of indications in a number of different animal 
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species, for example in cattle and sheep (Howell et al., 2008; Mena et al., 2001; Tollefsen et 
al., 2003), horses (Brown et al., 2008), pigs (Brown et al., 2004; Gravier et al., 2007) as well as 
cats (Brown et al., 2009; Ross et al., 2006; Walker et al, 2005) and dogs. In dogs mainly ex vivo 
delivery approach and viral vectors have been used in different disease models, primarily 
for treatment of hemophilia B, muscle dystrophies and in therapy of ischemic heart disease 
(Arruda et al. 2010; Banks & Chamberlain, 2008; Dixon & Spinale, 2009; Hasbrouck & High, 
2008; Haurigot et al., 2010; Herzog et al., 2001; Katz et al., 2010; Ohshima et al., 2009; L. 
Wang & Herzog, 2005; Z. Wang et al., 2007, 2009). 
The most straightforward introduction of foreign transgenes into skeletal muscle is simple 
intramuscular injection of naked plasmid DNA, which can result in a sustained transgene 
expression (Budker et al., 2000; Lu et al., 2003; Wolff et al., 1990). The main disadvantage of 
this method, which severely limits its therapeutic potential, is low transfection efficiency 
and pronounced variability of inter-individual levels of gene expression (Mir et al., 1999). 
Both described limitations of this gene delivery technique can be ameliorated by different 
methods, one of them being electroporation. 
Electroporation is a physical method for delivery of various molecules into the cells by 
transiently increasing permeability of cell membrane with application of controlled external 
electrical field to the target cells (Neumann et al., 1982). It displays effectiveness for a broad 
spectrum of applications, in both in vitro and in vivo settings. In vitro it is already routinely 
used as a method for intracellular delivery of a variety of molecules, e. g. RNA, DNA, dyes, 
ions, chemotherapeutic drugs, etc. In vivo it has shown a great potential for two prospective 
therapeutic approaches in oncology, electrochemotherapy and electrogene therapy (EGT), 
both already used in clinical practice in both human and veterinary medicine (Cemazar et 
al., 2008; Daud et al. 2008; Kodre et al., 2005; Mir et al., 1998; Pavlin et al., 2011; Reed et al., 
2010; Sersa et al., 2000; Tozon et al., 2001, 2005). This method of transgene delivery can be 
applied to almost any tissue in a living organism, with research focused primarily on tumor 
tissue, skin and skeletal muscle (Cemazar & Sersa, 2007). Electroporation based transfection 
of skeletal muscle or muscle targeted EGT has been proven to be one of the most efficient 
and simple methods among different nonviral delivery methods currently under 
investigation (Cemazar & Sersa, 2007; Gehl et al., 1999). It combines injection of therapeutic 
plasmid DNA into the muscle with subsequent electroporation of the target tissue, resulting 
in dramatically, up to 2000-times, increased long-term local gene expression lasting more 
than one year (Aihara & Miyaziki et al., 1998; Mir et al., 1999; Tevz et al., 2008).  
In the last few years, the number of reports on successful intramuscular EGT in dogs is 
steadily increasing. Therapeutic genes, delivered into canine skeletal muscle with this 
technique are genes encoding growth hormone releasing hormone (GHRH) (Bodles-
Brakhop et al., 2008; Brown et al., 2009; Draghia-Akli et al., 2002), human coagulation factor 
IX (hF.IX) (Fewell et al., 2001) and interleukin-12 (IL-12) (Pavlin et al., 2008). These studies 
showed a considerable clinical effect of intramuscular EGT in canine patients. GHRH EGT 
resulted in dramatically improved clinical condition of dogs with cancer, resulting in 
prolonged life span and improved quality of life (Bodles-Brakhop et al., 2008; Draghia-Akli 
et al., 2002). In dogs with chronic renal failure the same therapy improved kidney function 
and anemia associated with kidney disease, leading to overall improved health and survival 
rate (Brown et al., 2009). Intramuscular hF.IX EGT led to significant increase in levels of 
hF.IX in dogs, which can be predicted to have therapeutic effect in animal models of 
hemophilia B (Fewell et al., 2001). An important aspect of these studies is the fact that the 
procedure was successfully performed on both healthy and diseased dogs, demonstrating 
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that even debilitated, cachectic and immunocompromised animals are capable of systemic 
shedding of transgenes resulting in clinical effect of intramuscularly delivered therapeutic 
genes. 
IL-12 is a heterodimeric protein composed of two covalently linked subunits, a 35 kDa light 
chain (also known as p35 or IL-12α) and a 40 kDa heavy chain (known as p40 or IL-12). The 
discovery of IL-12 in 1989 revealed its strong effect on both innate immune system through 
induction of IFN-γ production from natural killer (NK) cells as well as on adaptive immune 
system through generation of cytotoxic T Lymphocytes (Kobayashi et al., 1989; Trinchieri et 
al., 1992). Based on these biological actions it was predicted that this cytokine is required for 
resistance to bacterial and intracellular parasites, as well as for the establishment of organ-
specific autoimmunity (Trinchieri, 2003) and was considered that it shows possible 
therapeutic potential for treatment of diseases, which would  favorably respond to its 
immunomodulating actions. With the additional discovery of its antiangiogenic effects 
(Voest et al., 1995), IL-12 became one of the most promising cytokines for treatment of 
malignant diseases. 
A model of mechanisms involved in the antitumor effects of IL-12 predict that IL-12 directly 
activates cells of the adaptive (CD4+ and CD8+ T cells) and innate arm of immunity by 
helping to prime T cells increasing their survival, enhancing T cell, and NK cell effector 
functions as well as promoting induction of IFN-γ secretion. IFN-γ in turn acts directly on 
tumor cells and other cell components within the tumor, by enhancing recognition of tumor 
cells by T cells through MHC class I processing and presentation and by modifications of 
extracellular matrix, which result in reduced antiangiogenesis and tumor invasion. The end 
result of these actions is impediment of tumor growth and ultimately eradication of the 
tumor. The first preclinical studies in the early 1990s with recombinant IL-12 protein in 
cancer treatment indeed showed its antitumor and antimetastatic activity (Brunda et al., 
1993; Nastala et al., 1994). Unfortunately, potent antitumor effect established on preclinical 
level did not translate to clinical setting, demonstrating only limited therapeutic effect with 
serious toxic side-effects in the first clinical studies (Atkins et al., 1997). Therefore new 
therapeutic approaches for in vivo delivery of IL-12 have been investigated, with gene 
transfer of IL-12 introducing safer and more effective treatment method compared to 
systemic application of recombinant protein. 
As one of therapeutic gene delivery methods, IL-12 EGT has been utilized in a number of 
different tumor models both on preclinical level and in clinical trials (Cemazar et al., 2010). 
Using electroporation, the therapeutic gene has been delivered into tumor tissue or skeletal 
muscle and EGT has been used either as a single therapy or in combination with other 
therapeutic genes and agents (e.g. IL-18, IL-27, herpes virus thymidine kinase, tetanus toxin 
fragment C) or different treatment methods, e.g. electrochemotherapy or radiotherapy 
(Cemazar et al., 2010; Kamensek & Sersa, 2008). These studies established that IL-12 EGT 
shows remarkable local and systemic antitumor effects, including significant growth delay 
and even achieving complete long-term regression of treated tumors, induction of long-term 
antitumor immunity, antimetastatic activity and prolongation of survival in treated animals. 
Direct antitumor effect in established tumors is generally better achieved with local 
intratumoral delivery of therapeutic gene, whereas intramuscular delivery results especially 
in good antimetastatic activity (Hanna et al., 2001; Lee et al., 2003; Li et al., 2005; Lucas et al., 
2002; Tevz et al., 2009).  
In preclinical studies the murine tumor models, which favorably responded to  IL-12 EGT, 
were melanoma (L.C. Heller & R. Heller, 2010),  lymphoma (Lee et al., 2003), soft tissue 
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sarcoma (Pavlin et al., 2009; Tevz et al., 2009) and a variety of different carcinomas (Cemazar 
et al., 2010; L.C. Heller et al., 2005). In clinical settings, intratumoral IL-12 EGT has been 
successfully used both in humans (Daud et al., 2008), as well as dogs (Cutrera et al., 2008; 
Pavlin et al., 2011; Reed et al., 2010). In all of presently published studies in tumor-bearing 
dogs, EGT has been performed with intratumoral delivery of IL-12 either alone (Chuang et 
al., 2009; Pavlin et al., 2011), or in combination with electrochemotherapy with bleomycin 
(Cutrera et al, 2008; Reed et al., 2010). The only published intramuscular IL-12 EGT in dogs 
was performed on healthy experimental beagles (Pavlin et al., 2008), showing feasibility, 
efficacy and safety of this approach. However, similar approach to IL-12 gene therapy in 
tumor-bearing companion animals has not yet been described. 
The aim of our study was to evaluate effects of intramuscular EGT with plasmid encoding 
human IL-12 in dogs with spontaneously occurring tumors. For this purpose, 1 mg of 
plasmid encoding human IL-12 was injected into m. semitendinosus of 6 patients with 4 
different tumor types.  Systemic transgene release and induction of IFN-γ response was 
determined by repeated measurements of hIL-12 and canine IFN-γ (cIFN-γ) in patients' sera. 
Possible side effects of the procedure were monitored with regular clinical examinations and 
determination of selected hematology and biochemistry parameters. 
2. Materials and methods 
2.1 Animals 
All animals participating in this study were referred to the Clinic for small animal 
medicine and surgery, Veterinary faculty of Ljubljana, University of Ljubljana, Slovenia, 
for evaluation of different types of spontaneously occurring tumors. Prior to inclusion, 
written consent for participation in the study was obtained from the owners and the study 
was approved by the Ethical Committee at the Ministry of Agriculture, Forestry and Food 
of the Republic of Slovenia (approval No. 323-451/2004-9). Six dogs of five different 
breeds corresponded to the inclusion criteria, their age ranging from 3 - 13 years (Table 1). 
Inclusion criteria for the study comprised at least one cytologically or histologically 
confirmed tumor nodule, good general health status of the animal with the basic 
hematology and biochemistry profile within reference limits and normal renal and 
cardiovascular function. In these animals intramuscular EGT was performed either as an 
adjuvant therapy to conventional therapeutical procedures, specific for each tumor type 
or as single therapy in a patient, where other therapies were not possible or acceptable by 
the owner.  
The study cohort comprised of three dogs with intermediately (i.e. grade II) (Figure 1) and 
poorly differentiated (i.e. grade III)  (Figure 2) mast cell tumors (MCT) in different clinical 
stages, and one dog with each: pulmonary histiocytic sarcoma (PHS) (Figure 3), 
osteosarcoma (OSA) (Figure 4) and mammary adenocarcinoma (MAC) (Table 1).  
One patient with MCT had metastatic disease involving local lymph nodes, and neither of 
patients had clinically detectable distant metastases. Two of the patients, one with MCT and 
one with mammary adenocarcinoma, had recurrent disease after marginal surgery. 
Histological or cytological diagnosis was established with examination of tumor biopsies 
and local lymph node fine needle aspiration in all tumors except OSA. Superficial tumors 
were measured in three perpendicular directions and their volume was calculated using the 
formula: V = a x b x c x π/6. 
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Fig. 1. Patient no. 2, German boxer with grade II MCT in the gluteal region, which was 
surgically removed and at the same time intramuscular EGT performed in the contralateral 
leg. Arrow indicats the position of the tumor. 
 
 
Fig. 2. Fine needle aspirate of poorly differentiated MCT (gradus III) in patient no. 3 (Giemsa 
stain). A: Tumor aspirate; B: Aspirate of prescapular lymph node with mast cell infiltrations 
(metastases of primary tumor in local lymph nodes) (arrows). 
Before the treatment, staging of the disease according to modified WHO criteria in each 
patient was performed with clinical examinations, abdominal ultrasonography, thoracic 
radiography and basic bloodwork with biochemistry profile. Bloodwork included complete 
blood count with differential white blood cell count, performed with an automated laser 
hematology analyzer (Technicon H*1, Bayer, Germany) with species-specific software (H*1 
Multi-Species V30 Software). Determination of selected biochemistry parameters (serum 
concentrations of urea and creatinine and activity of serum alkaline phosphatase and 
alanine aminotransferase) was performed using automated chemistry analyzer Technicon 
RA-XT (Bayer, Germany).  Basal determinations of serum concentrations of human IL-12 
and canine IFN-γ using ELISA kits (Human IL-12 Quantikine ELISA kit and Canine IFN-γ 
Quantikine ELISA kit, respectively, both R&D System, Minneapolis, MN, USA) were also 
performed.  
B 
A 
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Fig. 3. Patient no. 4 with pulmonary histiocytic sarcoma. A: Thoracic radiograph of the 
patient depicting a solid mass in caudal lobe of the lungs (arrow); B: Fine needle aspirate of 
the tumor showing large round typically vacuolated histiocytic cells with high degree of 
anisokariosis (Giemsa stain; 400 times magnification). 
 
 
Fig. 4. Radiograph of pelvis in patient no. 5 showing predominantly osteolytic lesions on the 
iliac bone involving pars compacta (arrow), consistent with radiological presentation of 
osteosarcoma. 
Each patient received one EGT treatment. In five of six treated animals, EGT was performed as 
an adjuvant therapy to conventional treatment procedures (Table 1). In all three dogs with 
MCT, tumor nodules were marginally surgically removed prior to or concomitantly with EGT 
and two of these patients also received systemic chemotherapy, which consisted of either 
vincristine and methyprednisolone protocol (0.5 – 0.7 mg/m2 and 1 mg/kg, respectively) or 
CCNU (lomustine, 60 - 90 mg/m2). In the patient with mammary adenocarcinoma, the tumor 
was surgically removed with marginal excision before performing EGT. The patient with 
pulmonary histiocytic sarcoma received one cycle of CCNU chemotherapy (60 mg/m2), 
A B 
www.intechopen.com
 Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous Canine Tumors 
 
305 
applied two weeks after EGT. The only exception, in which EGT was performed as a single 
therapy was the dog with OSA in which location of the tumor (pelvis) precluded surgical 
treatment and the owner refused palliative radiotherapy. 
 
Pt. 
No. 
Breed Age 
(yrs)/ 
Gender
Tumor type Tumor 
location 
Clinical 
stage 
Therapy (listed 
chronologically) 
1 German 
boxer 
7/M Mast cell tumor
Gradus III 
Front leg IIa  Marginal surgery 
 Systemic 
chemotherapy  
   (V+M 4 cycles) 
 EGT 
2 German 
boxer 
3/FS Mast cell tumor
Gradus II 
Hind leg Ia  Surgery with 
clear surgical 
margins 
concomitantly with  
EGT 
3 Lhasa-apso 13/FS Mast cell tumor
Gradus III 
Neck 
Metastases 
in local 
lymph 
nodes 
Recurrence 
after 
surgery 
IIIa  Marginal surgery 
 EGT 
 Systemic 
chemotherapy  
(V+M 2 cycle; 
CCNU 1 cycles) 
4 Bernese 
mountain 
dog 
6/M Pulmonary 
histiocytic 
sarcoma 
Lungs N/A  EGT 
 CCNU 1 cycle 
5 Doberman 
Pinscher 
8/FS Osteosarcoma Pelvis 
(ilium) 
N/D  EGT 
6 Crossbreed 11/FS Mammary 
adenocarcinoma
Mammary 
gland (D2-4)
Recurrence 
after 
surgery 
IIIb  Surgery (partial 
mastectomy) 
 EGT 
a - clinical stage according to modified WHO clinical staging system for mast cell tumors (Thamm & 
Vail, 2007) 
b - clinical stage according to Owen LN, Classification of tumors in domestic animals, Geneva, 1980, 
WHO 
M: male, FS: spayed female, V+M: vincristine/methylprednisolone chemotherapy protocol, N/A: not 
applicable, N/D: not determined 
Table 1. Summary of dogs' characteristics and histories 
2.2 Plasmid preparation 
The pORF-hIL-12 plasmid (InvivoGen, Toulouse, France), encoding human IL-12, was 
selected based on published data indicating that canine and human IL-12 share 
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approximately 90% genetic identity based on amino acid sequence analysis (Buettner et al., 
1998). Furthermore, it has already been shown that in in vitro settings, human IL-12 activates 
proliferation of canine peripheral blood mononuclear cells (PBMC), consequently triggering 
a number of immune responses in canine PBMCs (Phillips et al., 1999). The plasmid was 
prepared using the Qiagen Maxi Endo-Free kit (Qiagen, Hilden, Germany), according to 
manufacturer's instructions and diluted to concentration of 1 mg/ml. Purified plasmid DNA 
was subjected to quality control and quantity determinations, performed by agarose gel 
electrophoresis and by means of spectrophotometry. 
2.3 Electrogene therapy procedure 
EGT was performed in the patients under general anesthesia, which was induced with 
propofol (Propoven 10 mg/ml, Fresenius Kabi Austria GmbH, Graz, Austria) and maintained 
with isoflurane (Forane, Abbott Laboratories LTD, Queensborough, UK). During the 
anesthesia the animals were receiving Hartmann's solution (B. Braun Melsungen AG, 
Melsunen, Germany) at the rate of 10 ml/kg of bodyweight/h. Hair on the right femoral 
region was clipped and the area surgically prepared, followed by intramuscular injection of 1 
mg of sterile solution of therapeutic plasmid into m. semitendinosus using 1 ml syringe with 22 
G needle (Figure 5). The position of the needle was slightly changed during the emptying of 
syringe, allowing the content of syringe to infiltrate the target tissue more uniformly. Ten 
minutes later, electric pulses were applied to plasmid infiltrated muscle with electric pulses 
generator CliniporatorTM (IGEA s.r.l., Carpi, Italy), using intramuscularly placed needle 
electrodes N-18-4B (IGEA s.r.l., Carpi, Italy), which consist of 2 arrays, each composed of 4 
electrodes with 4 mm distance between them. One HV pulse (600 V/cm, 100 μs) was 
delivered, followed by 4 LV pulses (80 V/cm, 100 ms, 1 Hz), with 1 second lag between the 
HV and LV pulses. Postsurgically, analgesia was provided to all dogs with single intravenous 
application of carprofen (Rimadyl, Pfizer Animal Health, Dundee, United Kingdom; 4mg/kg 
of bodyweight). When they fully recovered from anesthesia, they were released from the 
hospital. The treated femoral area was protected with suitable dressing in order to prevent 
licking and any possible contact of humans or animals with the electroporated region. 
2.4 Evaluation of response to the therapy 
Animals were examined 7, 14 and 28 days after EGT and monthly thereafter until any 
cytokine was detected in three consecutive samples. Each follow-up included the same 
diagnostic procedures as pre-therapy examination. At each examination, response to the 
therapy was evaluated with determination of serum concentrations of both previously 
mentioned cytokines, as described above, measurements of tumor nodules, where 
applicable and notification of possible side effects.  For evaluation of local effects, 
measurements of tumor nodules, where applicable, were performed. 
2.5 Evaluation of possible side effects of the procedure 
The possible occurrence of local and systemic side effects was evaluated at each follow-up 
with clinical examination of the patients, assessment of electroporated area for appearance 
of any adverse effects to either plasmid solution or electroporation of the tissue (e.g. 
swelling, erythema, pain, secretions, tissue necrosis etc). Blood samples were collected at 
each follow-up for the same bloodwork as during the staging of the disease prior to EGT in 
order to evaluate possible systemic toxicity of the procedure. 
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Fig. 5. Intramuscular EGT procedure. A: Surgically prepared femoral region;  
B: Intramuscular application of plasmid solution; C: Transcutaneous intramuscular 
placement of needle electrodes. 
3. Results 
3.1 Response to the therapy 
In four out of six treated patients, serum concentrations of human IL-12 and/or canine IFN-
γ were detected, among these responders were all three patients with MCT and  the patient 
with PHS (Figure 6). Human IL-12 was detected in serum of a MCT patient 7 days after the 
procedure in concentration 17 pg/ml. IFN-γ was detected in single or multiple samples of 
all four mentioned patients, in concentrations ranging from 6.5 to 246.8 pg/ml, 4 to 28 days 
after the EGT procedure (Table 2). None of the patients had any detectable hIL-12 or IFN-γ 
in samples taken before the EGT procedures. 
In these four patients, surprisingly long survival times after EGT were achieved (Table 2), 
even though intramuscular IL-12 EGT did not have any effect on volumes of measurable 
tumor nodules. The dog with recurrent grade III MCT and lymph node metastases (clinical 
stage III) and the dog with PHS received additional chemotherapy 2 weeks after EGT; 
however the chemotherapeutic protocols were shortly discontinued due to severe side 
effects both patients developed. Even though the delivered chemotherapy in these two 
patients was inadequate to be effective and result in potential systemic antitumor effect, the 
dog with MCT survived 6 and the dog with PHS 8 months after the EGT procedure. The 
other two patients with detected IL-12 and/or IFN-γ had grade II and grade III MCTs. In the 
dog with grade II MCT (clinical stage I), the tumor nodule was marginally surgically 
removed and at the same time intramuscular IL-12 EGT performed, without any additional 
therapy. In the last dog, grade III MCT (clinical stage II) was treated with marginal excision 
and full chemotherapy with vincristine and methylprednisolone, followed by intramuscular 
A B 
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IL-12 EGT. These two patients had complete response to the therapy without local 
recurrence or metastatic disease, surviving for over 4 and 3 years, respectively. 
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Fig. 6. Graph representing percentage of treated animals, which responded to intramuscular 
EGT with systemic release of either cytokine (i.e. responders) versus animals without 
systemically detectable cytokine (i.e. nonresponders). 
 
Pt. 
No. 
Tumor type IL-12  
(pg/ml)
IFN-γ  
(pg/ml) 
Timing of 
sample 
collection 
after EGT 
Follow-
up after 
EGT 
Response 
to the 
therapy 
1 Mast cell tumor 
Gradus III 
17.0 
- 
- 
246.8 
7 days 
28 days 
> 3 years CR 
2 Mast cell tumor 
Gradus II 
- 6.5 7 days > 4 years CR 
3 Mast cell tumor 
Gradus III 
- 80 7 days 6 months PD 
4 Pulmonary 
histiocytic 
sarcoma 
- 
- 
37.1 
104.2 
7 days 
14 days 
8 months SD 
5 Osteosarcoma - -  5.5 
months 
SD 
6 Mammary 
adenocarcinoma 
- -  2 months PD 
Table 2. Response to the therapy in the treated patients. CR: complete response, PD: 
progressive disease, SD: stable disease 
In the other two patients (OSA and recurrent extensive MAC), neither cytokine was detected 
in serum at any time point after surgery. The dog with OSA survived for 165 days without 
17% 67%
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any additional treatment, except pharmacological pain management and was euthanized 
due to progression of pain, unresponsive to analgesic therapy, without any radiologically 
evident distant metastases. The patient with MAC was euthanized 2 months after EGT due 
to progression of the disease (growth of tumor). 
 
 Before 
EGT 
Week 1 
 
Week 4
 
Week 5
 
Week 
6 
Week 8 
 
Week 11
 
Week 
14 
Ref. 
values 
Ther-
apy: 
 V+M: 
Cycle 1 
V+M: 
Cycle 2 
V+M: 
Stop 
 CCNU: 
Cycle 1 
CCNU: 
Stop 
  
WBC 13.64 21.41 15.84 3.29 16.25 19.78 13.51 12.96 6.0-18.0 
RBC 8.45 6.85 6.12 6.55 7.10 6.35 6.89 6.59 5.1-8.5 
HCT 0.57 0.47 0.44 0.47 0.52 0.47 0.51 0.48 0.35-
0.55 
Neutro 8.43 16.48 12.27 1.29 12.31 17.25 10.48 12.2 3.0-11.8 
Urea 10.2 N/D 9.2 12.1 11.9 13.2 8.03 10.5 3.0-12.5 
Crea 107.4 N/D 90.6 111.3 114.9 109.5 96.9 118.1 44.2-
132.6 
SAP 92.6 77.0 113.3 N/D 107.5 112.9 671.1 287.9 25-117 
ALT 65.4 64.6 50.7 N/D 62.1 78.1 312.5 84.1 23-90 
Table 3. Hematological and biochemistry results in the patient No. 3 with high grade MCT, 
receiving IL-12 EGT, followed by two different systemic chemotherapy protocols, applied 
only partially due to induction of marked side effects. Clinically relevant abnormalities in 
the bloodwork subsided after discontinuation of chemotherapy, demonstrating that the 
toxicity was caused by chemotherapy and not IL-12 EGT WBC: white blood cells, RBC: red 
blood cell, HCT: hematocrit, Neutro: neutrophils, Crea: creatinine, SAP: serum alkaline 
phosphatase, ALT: alanine aminotransferase, V+M: vincristine/methylprednosolone 
chemotherapy protocol, N/D: not detected 
3.2 Side effects of the procedure 
In order to evaluate possible side effects at each follow-up, clinical examination as well as 
bloodwork with emphasis on kidney and liver function of patients was performed, due to 
known hepato- and nephrotoxicity of systemic recombinant IL-12 based therapy. We did not 
detect any side effects, which could be attributed to IL-12 toxicity, with hematological and 
biochemistry parameters staying within reference limits immediately after the procedure. In 
two of the patients marked hematological abnormalities were detected after induction of 
chemotherapy after EGT, which were attributed to the used chemotherapeutic agents, rather 
than EGT, since they were typical and well documented side effects of selected 
chemotherapy (i.e. leucopenia due to immunosuppression with vincristine and activation of 
serum alkaline phosphatase and alanin aminotrasferase due to hepatotoxicity of CCNU) 
(Table 3). In these two patients the abnormal values returned within the reference limits 
shortly after discontinuation of chemotherapy. 
EGT procedure also did not cause any local side effects, for example swelling or 
inflammation of the electroporated area despite local invasiveness of the procedure, which 
was performed with intramuscularly placed needle electrodes (Figure 7). 
www.intechopen.com
 Targets in Gene Therapy 
 
310 
 
Fig. 7. The site of intramuscular EGT (arrow) in patient with mammary adenocarcinoma 2 
days after the procedure without any signs of local side effects following invasive procedure 
4. Discussion 
Results of our study indicate that in canine cancer patients, intramuscular IL-12 EGT is a safe 
procedure, which can result in systemic shedding of human IL-12 and possibly trigger IFN-γ 
response in treated patients, leading to prolonged disease free period and survival of treated 
animals. 
In all of our patients, EGT was performed with a single intramuscular application of 1 mg of 
therapeutic plasmid encoding human IL-12, followed by delivery of one high voltage pulse 
and four low voltage pulses. Four out of six patients responded to the therapy with 
systemically detectable human IL-12 and/or IFN-γ concentrations. Systemic release of 
encoded transgene products in sufficient concentrations to elicit biological effect was 
already demonstrated after intramuscular EGT with different therapeutic genes in dogs 
(Brown et al., 2009; Draghia-Akli et al., 2002; Fewell et al., 2001; Pavlin et al., 2008; Tone et 
al., 2004). In preclinical studies, intramuscular IL-12 EGT displayed systemic antitumor 
effect due to systemic release of IL-12 and IFN-γ in several tumor models (Hanna et al., 2001; 
Lee et al., 2003; Lucas et al., 2002, 2003; Tevz et al., 2009; Zhu & Li, 2008). Compared to these 
studies, we achieved relatively low systemic concentrations of IL-12, whereas the serum 
concentrations of IFN-γ were comparable to concentrations achieved in experimental 
animals (Lucas et al., 2002; Tevz et al., 2009).  
It is possible that more pronounced response to the therapy with higher systemic cytokine 
concentrations in treated patients could be achieved with application of either higher 
plasmid dose or with more repetitions of EGT procedure. Even though Fewell and 
colleagues achieved systemic release of therapeutic concentration of human coagulation 
factor IX with a single intramuscular EGT of therapeutic plasmid, extremely high dose of 
therapeutic plasmid had to be delivered, even up to 3 mg of plasmid/kg of bodyweight 
(Fewell et al., 2001). Similarly, different experiments showed that in large animals the level 
of systemically secreted transgene product is dose and volume dependent with increased 
transgene expression correlating with increase in plasmid dose and volume until a certain 
saturating dose (Khan et al., 2003). On the other hand, in studies where therapeutic plasmid 
encoding GHRH was used, biological effects were achieved after single EGT with plasmid  
doses as low as 10 - 100 μg of plasmid per kg of bodyweight (Brown et al., 2009; Draghia-
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Akli et al., 2002; Tone et al., 2004). As established in preclinical research, size and 
construction of plasmid plays an important role in effectiveness of electroporation-based 
delivery of DNA in vivo (Cemazar & Sersa, 2007). This fact could in part explain such 
striking differences in plasmid doses, which were needed in different studies on dogs to 
exert systemically detectable transgene product release. Therefore in the future, 
optimization of dose with dose escalation studies should be attempted for each therapeutic 
plasmid. 
Another possible improvement of systemic transgene release could be in multiple 
consecutive repetitions of EGT procedure. Several previous studies on different animal 
tumor models demonstrated, that more than one either intratumoral or intramuscular 
application of plasmid encoding IL-12 is necessary to achieve adequate therapeutic response 
in treated animals, even without systemically detectable IL-12 concentrations (Heinzerling et 
al., 2001; L.C. Heller et al., 2006; Lucas & R. Heller, 2003; Tevz et al., 2009). For example in 
melanoma tumor model significantly better therapeutic response was achieved with 
increasing the number of intratumoral applications or with addition of intramuscular gene 
delivery (Lucas & R. Heller, 2003). Similarly, four consecutive intramuscular IL-12 EGTs 
resulted in a significantly better systemic release of IL-12, compared to a single EGT 
procedure (Tevz et al., 2009).  
Another possible explanation for nonresponders is that the timing of the samples collections 
was not optimal, since the samples were collected every 1 to 2 weeks in the first month and 
monthly thereafter. According to published literature, the time of the highest systemic 
release of IL-12 and IFN-γ achieved after intramuscular IL-12 EGT is greatly variable. In 
different studies, the highest serum concentration of IL-12 was achieved between 4 and 17 
days after EGT procedure, followed by the elevation of IFN-γ serum level with 
approximately 4-5 days delay (Lucas et al., 2002; Tevz et al., 2009). Kinetics of systemic IL-12 
release varies even within the same species. In mice intramuscular EGT with the same 
plasmid dose results in significantly different systemic transgene release depending on 
strain of treated animals (Tevz et al., 2009). For example, in C57Bl/6 strain, serum 
concentration of IL-12 reached peak on day 6 (Tevz et al., 2009) or day 10 (Lucas et al., 2002) 
after EGT and abruptly declined to approximately half of peak concentration in the next few 
days. On the other hand, in A/J mice strain, serum concentration of IL-12 reached plateau 
by day 6, which lasted until approximately day 14, followed by a slow decline. Even more 
surprising is the fact, that in C57Bl/6 strain approximately three-times higher serum 
concentrations of IL-12 were achieved compared to A/J strain. The underlying mechanisms 
responsible for these discrepancies in transgene expression are not yet explained. Therefore 
even in a relatively homogenous group of experimental animals, determination of optimal 
serum collection timing is not as straightforward. Based on these findings, in such a 
heterogenic group as dogs, greatly varying in size and other physical attributes, a more 
thorough examination of cytokine release after intramuscular EGT should be attempted. 
Data on kinetics of transgene release in dogs after intramuscular IL-12 EGT would be 
helpful for clinical application to determine the best time intervals for treatment repetitions 
in each individual patient in order to achieve the maximum therapeutic effect. 
In our study, intramuscular EGT did not exert such pronounced local antitumor effect on 
treated tumors compared to direct intratumoral IL-12 EGT (Chuang et al. 2009; Pavlin et al., 
2011). In four of our patients, where tumors were not surgically removed and the size of 
intact tumors could be repeatedly measured, there was no regression in tumor size after 
performed EGT. In comparison, with intratumoral IL-12 EGT volumes of treated canine 
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mast cell tumors reduced significantly by over 50% (Pavlin et al., 2011) and even complete 
remissions were achieved in experimentally induced transmissible veneral tumors in dogs 
(Chuang et al., 2009). This discrepancy in antitumor effectiveness of intratumoral versus 
intramuscular IL-12 EGT has already been shown in experimentally induced tumors in 
preclinical studies. Usually, intratumoral IL-12 EGT results in better direct antitumor effect, 
demonstrated as growth delay and reduction of treated tumors' size, compared to 
intramuscular route of gene delivery (Lucas et al., 2002, 2003). On the other hand, 
intramuscular IL-12 EGT exhibits pronounced antimetastatic effect with high systemic 
concentrations of IL-12 and stable induction of IFN-γ response (Hanna et al., 2001; Tevz et 
al., 2009). With intramuscular route of therapeutic gene delivery, relatively low proportion 
of complete regressions is achieved, typically around 15-40%, depending on model of 
treated tumor (Lee et al., 2003; Lucas et al., 2003; Tevz et al., 2009), whereas in some of the 
reported studies, complete response with intramuscular IL-12 EGT was not achieved (Hanna 
et al., 2001). In comparison, intratumoral IL-12 EGT generally results in approximately 60-
80% complete response rate in treated tumors (L.C. Heller et al., 2006; Lucas et al., 2003), 
even reaching 100% curability (Pavlin et al., 2009). Based on results of preclinical work it can 
be concluded that the main advantage of intramuscular IL-12 EGT lies in its systemic effects, 
namely antimetastatic activity and consequently prolongation of treated animals survival 
time (Lee et al., 2003; Lucas et al., 2002; Tevz et al., 2009;  Zhu & Li, 2008). 
Even though we treated a relatively small number of animals, their survival times after EGT 
were longer compared to survival times associated with specific tumor types from literature 
review. For example, the patient with PHS was euthanized over 8 months after EGT and a 
single application of CCNU due to progression of clinical signs, namely dispnoa and 
exercise intolerance. According to the literature, median survival time for dogs with PHS, 
treated with full CCNU chemotherapy (four consecutive applications every 3 weeks), is 96-
106 days (Fulmer & Maudlin, 2007; Rassnick et al., 2010; Skropuski et al., 2007). In this 
patient, CCNU therapy was discontinued after one application due to pronounced 
hepatotoxicity, therefore probably exerting only negligible therapeutic effect. The patient 
with OSA survived 5.5 months, whereas reported median survival time for dog with OSA 
without any treatment is 1 - 3 months (Selvarajah et al., 2009). In three patients with higher 
grade MCTs, relatively long survival times were achieved. In canine MCT, survival strongly 
correlates with histological grade of the tumor and clinical stage of the disease (Patnaik et 
al., 1984), with very high recurrence rate after surgical therapy in more aggressive higher 
grade tumors (Fox, 2002; Thamm & Vail, 2007). The patient with grade III MCT in clinical 
stage III of the disease with recurrent growth of tumor tissue immediately after marginal 
resection of MCT and metastases in local lymph nodes survived for 6 months after EGT 
before being euthanized due to progression of the disease. Two weeks after EGT, 
consecutively two different systemic chemotherapies were started, each discontinued 
shortly after induction due to severe side-effects, therefore none of the chemotherapy 
protocol was administered long enough to reach any therapeutic potential.  In comparison 
to these three patients, veterinary literature reports approximately 30% local recurrence of 
incompletely excised grade II MCT (Thamm & Vail, 2007) and only 7% partial response rate, 
without any complete responses, to full chemotherapy protocol utilizing vincristine (McCaw 
et al., 1997). For patients with grade III MCT, median survival time of 3 months after surgery 
without any additional therapy is reported (Thamm & Vail, 2007). 
In preclinical studies intramuscular IL-12 EGT conveyed in successful transgene expression 
and systemic release of significant concentrations of IL-12, therefore raising concerns 
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regarding safety of this therapeutic approach, based on described toxicity of systemic 
application of recombinant IL-12. It has been established that systemic recombinant IL-12 
therapy can exhibit serious adverse effects, including elevated body temperature, 
headaches, nausea and vomiting, nephro- and hepatotoxicity (Leonard et al., 1997) and 
application of high dose of rIL-12 was linked with temporary immunosuppression 
(neutropenia, lymphopenia, thrombocytopenia and anemia) (Motzer et al., 1998), which 
would not be favorable for effective immunotherapy. Therefore monitoring of renal and 
hepatic function in patients receiving any IL-12 based therapy is strongly recommended. 
These adverse effects are presumably due to toxicity of IFN-γ response induced by 
circulating IL-12 (Car et al., 1999; Leonard et al., 1997; Ryffel, 1996). Toxic side effects in 
human patients appeared when serum concentration of IFN-γ exceeded 6.0 ng/ml (Leonard 
et al., 1997), whereas experimental animals tolerated serum concentrations as high as 300 
ng/ml without any severe adverse reactions (Leonard et al., 1997). A comprehensive study 
of intratumoral IL-12 EGT toxicity has been conducted, with evaluation of changes in weight 
and blood biochemistry and haematology parameters, as well as histopatological 
examination of several different tissues of treated animals (L.C. Heller et al., 2006). Even 
though a pronounced antitumor effect was achieved on melanoma tumor model, no 
significant side effects of the procedure were observed (L.C. Heller et al., 2006). Although 
sporadically, significant abnormalities in bloodwork were detected, they were clinically 
irrelevant for the treated animals. The only histopathologic abnormality was late-onset 
inflammation associated with the kidney without any biochemical markers of decreased 
kidney function. Nevertheless, these findings did not reflect in any impairment of general 
health of treated animals. Nevertheless, in this study no systemically detectable 
concentrations of either IL-12 or IFN-γ were achieved. Therefore its conclusions can not 
directly demonstrate safety of intramuscular IL-12 EGT as well, since intramuscular route of 
therapeutic gene administration can result in significant systemic concentrations of both IL-
12 and IFN-γ. In preclinical studies, side-effects of the procedure were not so thoroughly 
investigated, however, available data show that intramuscular IL-12 EGT, compared to 
intratumoral, can exhibit more pronounced, but still tolerable side effects, mainly transient 
significant reduction of bodyweight at the highest serum concentrations of IL-12 and IFN-γ 
(Tevz et al., 2009). 
Clinical status of all animals enrolled in our study remained unaltered for the first 8 weeks 
after the EGT procedure. In the two patients with progressive disease (one patient with MCT 
and a patient with MAC), deterioration of general health was observed after 6 and 2 months, 
respectively, which reflected the increased tumor burden and was not a consequence of any 
toxic effects of the procedure. Hematology as well as biochemistry parameters of collected 
blood samples remained mostly within reference limits throughout the observation period. 
Few clinically significant alterations were observed in two patients receiving systemic 
chemotherapy. In the patient with PHS elevation of serum activities of enzymes ALT and SAP, 
which are biomarkers of liver function, was observed. However, this change occurred a week 
after induction of chemotherapy with CCNU, which exhibits known hepatotoxicity (Kristal et 
al., 2004). In the first two weeks after EGT, before the chemotherapy was started, no 
abnormalities in bloodwork were observed in this patient, despite detecting elevated serum 
levels of IFN-γ in blood samples collected 7 and 14 days after EGT. Furthermore, the increase 
in activities of both enzymes was only transient and their values normalized immediately after 
cessation of systemic chemotherapy. Similarly, transient haematological abnormalities were 
detected in the patient with MCT, receiving first immunosuppressive chemotherapy consisting 
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of vincristine and methylprednisolone and later CCNU. Bloodwork alterations were related to 
toxicity of these chemotherapy protocols, since they were displayed only after induction of 
chemotherapy and not around the time, when elevated levels of IFN-γ in patient's serum was 
detected. Other patients with systemically detectable IFN-γ, even as high as 246.8 pg/ml, did 
not display any abnormalities in their bloodwork assays. Therefore we can conclude, that the 
observed hepatotoxicity and immunosuppression were due to pharmacological agents rather 
than a side effect of IL-12 gene therapy.  
5. Conclusion 
In conclusion, the results of this study indicate, that intramuscular IL-12 EGT in dogs with 
spontaneously occurring tumors, is a feasible, simple and safe procedure, which exerts 
systemic transgene release of IL-12 and induction of IFN-γ response in treated animals, 
making it promising treatment modality in veterinary medicine. In the future, refinement of 
treatment protocols in different canine tumors should be performed, with respect to 
investigating kinetics of cytokine release, defining optimal plasmid dose, number of 
treatment repetitions and effect of combination with other treatment protocols (e.g. local 
intratumoral plasmid delivery or electrochemotherapy) in order to achieve effective long-
term antitumor effect in canine cancer patients. 
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